News

Video

HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

Author(s):

Erika P. Hamilton, MD

Erika Hamilton, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.

Related Videos
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA
A panel of 3 experts on breast cancer
Paolo Tarantino, MD
A panel of 3 experts on breast cancer
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study
Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis
Related Content
FDA
June 17th 2024

FDA Places Partial Clinical Hold on Phase 1 Trial of YL202 in Advanced NSCLC and Breast Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Brittany Bychkovsky, MD, MSc, of Dana-Farber Cancer Institute
June 11th 2024

Enhancing the Referral Process for Genetic Testing Represents Key Next Step in Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Lydia Pace, MD, MPH
June 5th 2024

A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer

Shengfeng Li
June 3rd 2024

Bevacizumab Biosimilar Avzivi Receives Positive CHMP Opinion